An In Vitro Alternative For Predicting Systemic Toxicity. By: James McKim, Ph.D., DABT Chief Science Officer
|
|
- Justina Stewart
- 5 years ago
- Views:
Transcription
1 An In Vitro Alternative For Predicting Systemic Toxicity By: James McKim, Ph.D., DABT Chief Science Officer
2 What is Systemic Toxicity and What do We Want From Alternative Methods? Toxicity that occurs after a chemical is absorbed into general circulation Acute systemic toxicity Single dose, and short exposure time Intrinsic toxicity of a chemical, LD50, organ effects Subacute systemic toxicity Repeated-dose study, typically 14 day Information on toxicity following repeated exposure Helps establish doses for subchronic studies Subchronic systemic toxicity Repeated-dose, typically 28 and 90 days Organ specific effects Establish NOAEL and LOAEL Regulatory implications FDA and EPA Chronic systemic toxicity
3 The Goal is to Predict Human Systemic Toxicity Most value = Subchronic Realistically What data are required for risk assessment NOAEL, LOAEL RfD, Benchmark dose Ideally
4 Building an In Vitro Model to Predict Repeat Dose Systemic Toxicity is Too Complex to Achieve Within the Next 10 Years! Most models focus on predicting organ specific toxicity BARRIER to SUCCESS Alternative approach is to identify a plasma concentration that results in general systemic toxicity Proprietary to CeeTox, Inc.
5 Relating Plasma Concentration to Toxicity Start with pharmaceuticals Intended for internal exposure at higher doses Environmental chemicals typically not intended to be ingested, exposure to lower doses, but for longer times Develop a means to estimate the plasma concentration where general toxicity would occur Develop a relationship between concentration response curves in vitro and Cmax in vivo at the dose where toxicity was observed in rat 14-day repeated oral dose studies Clinical chemistry Histopathology
6 The Relationship Between In Vivo Plasma Concentration (Bioavailability) and Toxicity Provides the Basic Model JL Stevens (2006) Chem Res Toxicol 19, Toxicity increases with potency = target Cell models that lack target show toxicity = chemistry Proprietary to CeeTox, Inc.
7 Developing the Hypothesis and Testing it When the in vivo Cmax for toxicity is identified at steady state for the lowest dose that results in toxicity, and compared to in vitro concentration response curves for toxicity, a relationship can be identified that enables the prediction of the in vivo plasma concentration where general toxicity would be expected to occur.
8 Building the Predictive Model Based on Empirical Data Sets Acquired in vivo data for pharmacokinetic parameters Developed concentration response data in vitro Based on multiple endpoint analysis developed a relationship between in vivo and in vitro data sets Tested the model with small number of drugs Validated model in large blinded study
9 Focus on Cell Biology and Physical Chemical Properties Improves the Model Biochemical Function Membrane Integrity Mitochondrial Function Cell Proliferation Redox-State Oxidative Stress Apoptosis Pharmacology CNS receptors Cardiovascular receptors and ion channels Physical-Chemical Properties Solubility Partition coefficients Pka Protein binding Metabolic stability Metabolic activation Transporter interaction Pharmacokinetic Parameters Clearance Bioavailability Volume of distribution
10 Selecting a Cell Model That Consistently Provides Accurate Data Rat hepatoma (H4IIe) Cell line Retains oxidative metabolism Low constitutive metabolism Accepts a wide range of serum concentrations
11 Analysis of In Vitro Concentration-Response to In Vivo Plasma Levels Multiple endpoints improve interpretation Membrane integrity Cell number or mass Mitochondrial function Analysis and comparison to in vivo plasma C max Development of weighting factors for each endpoint Result was an estimate of the plasma concentration where toxicity would be expected to occur (C tox )
12 Multiple Endpoints Are Essential For Correct Interpretation of In Vitro Data CMPD H4IIE 24HR Cell# MemTox MTT ATP GSH % Control FIG. A: Exposure Concentration (µm)
13 Determining Weighting Factors Membrane integrity Highest weight = cell death Concentration response and potency Time adjustment Mitochondrial function Moderate weighting Concentration response and potency Time adjustment
14 Evaluating Assumptions Against Rat In Vivo Data 100 R2 = Keto (rat) Predicted Concentration (um)
15 In Vitro Toxicity Data Correlates With Adverse Effects in Animals and Humans CHLOROQUINE H4IIE 24HR C tox = 5µM Cell# MemTox MTT ATP Rat actual C tox = 8 µm, Human actual C tox = 1-3 µm KETOCONAZOLE H4IIE 24HR C tox = 55 µm Cell# MemTox MTT ATP Exposure Concentration (µm) C tox = 1 METHOTREXATE H4IIE 24HR , FIG. A: Exposure Concentration Cell# MemTox MTT ATP Rat actual C tox = 0.7 µm, Human actual C tox = 0.88 µm % Control Rat Actual Ctox = 60 µm, Human actual Ctox = 30 µm Exposure Concentration (µm)
16 Metabolic Activation Identifies False Negative Results Tacrine = liver Flutamide = liver Acetaminophen = liver GSH Depletion relative to no drug control after 3.5 hr incubation with induced microsomes % GSH relative No Drug Flutamide NEM Acetaminophen Tacrine Test Article Full Reaction -NADPH reaction
17 Determining Relevance to Human Systemic Toxicity Ctox (µm) Azathioprine 1 1e-8 1e-7 1e-6 1e-5 1e-4 1e-3 max therapeutic [plasma] (log M) Ctox = 5 µm MTPC = 8 µm In vitro margin of safety <= 1 Proprietary to CeeTox, Inc.
18 Azathioprine: Inhibits Purine Synthesis and Produces Toxicity Under Clinical Conditions AZATHIOPRINE H4IIE 24HR AZATHIOPRINE H4IIE 24HR % Control Cell# MemTox MTT ATP GSH % Control Isoprostane (pg/ml) GSH ISO FIG. A: Exposure Concentration (µm) FIG. B: Exposure Concentration (µm) 0 AZATHIOPRINE H4IIE 24HR Caspase 3 Extremely Toxic C tox = < 5 µm Fluorescence Units FIG. C: Exposure Concentration (µm) Proprietary to CeeTox, Inc.
19 There is Good Concordance Between Predicted Toxicity Validated to Rat Data and Human Clinical Data Ctox (µm) Thioridazine Azathioprine 1 1e-8 1e-7 1e-6 1e-5 1e-4 1e-3 max therapeutic [plasma] (log M)
20 THIORIDAZINE H4IIE 24HR Cell# MemTox MTT ATP Exposure Concentration (µm) Ctox = 11 µm MTPC = 6 µm In vitro margin of safety = 1.83
21 Drug Potency Can Influence Plasma Concentration and Toxicity Valproic acid Ctox (µm) Paroxetine Chloroquine Thioridazine Azathioprine 1 1e-8 1e-7 1e-6 1e-5 1e-4 1e-3 max therapeutic [plasma] (log M)
22 Antidepressant Paxil (SSRI) Considered Safe Under Appropriate Use: Rare Incidences of Hepatotoxicity Paroxetine H4IIE 24HR FIG. A: Exposure Concentration Cell# MemTox MTT ATP Ctox = 15 µm MTPC = 0.3 µm In Vitro Margin of Safety = 50
23 Predicting Bioavailability of a New Drug and Maximum Therapeutic Plasma Concentration In Vitro CL int (human microsomes) Scaled in vitro CL int Calculate bioavailability (%f) f = 1 E E = f u x CL int / Q H Kuhnz and Gieschen (1998) Drug Metab Disp 26, 1120.
24 What is Systemic Toxicity and What do We Want From Alternative Methods? Toxicity that occurs after a chemical is absorbed into general circulation Acute systemic toxicity Single dose, and short exposure time Intrinsic toxicity of a chemical, LD50, organ effects Subacute systemic toxicity Repeated-dose study, typically 14 day Information on toxicity following repeated exposure Helps establish doses for subchronic studies Subchronic systemic toxicity Repeated-dose, typically 28 and 90 days Organ specific effects Establish NOAEL and LOAEL Regulatory implications FDA and EPA Chronic systemic toxicity
25 Predicting a Rat Acute Oral LD50 Dose Collaborative research effort with LOREAL Paris Integrative or systems biology + Computational Toxicology Multiple endpoints related to cell health Receptor binding data (pharmacology) Physical Chemical parameters Approach has been evaluated with more than 200 chemicals Posters at the World Congress in Rome 2009, SOT 2010 Results show that an integrated in vitro approach can provide good estimates of an LD50
26 Addition of Pharmacology and Physical Chemistry Properties Improves Model Performance Performance of the standard model at the LD50 threshold of 500 mg/kg Performance of the integrated model at the LD50 threshold of 500 mg/kg REDUCTION OF THE FALSE NEGATIVE RATE (yellow area)
27 Conclusions There is a robust model capable of identifying acute and subchronic systemic toxicity (Today) Chemicals can be evaluated for systemic toxicity potential High level of concordance with in vivo toxicity An acute LD50 can be determined
28 Future Improvements to the Model Develop a drug database with animal preclinical data and in vitro toxicity data Determine a calculation for NOAEL and LOAEL Broaden the chemical space to include nonpharmaceutical agents and test the model
29 CeeTox Overview of Services a wide range of in vitro toxicology and safety assessment services Systemic Toxicity Services CTOX Panel Acute Toxicity Screen In vitro LD50 (acute tox) Dermal Toxicity Percutaneous Absorption Corrosion Irritation Sensitization Photo Toxicity Ocular Toxicity Endocrine Disruption Estrogen receptor (ER) binding Estrogen transcriptional activation Androgen receptor (AR) binding Steroidogenesis Aromatase Organ Specific Toxicity Models Heart (CardioTox ) Kidney Liver CYP Induction/Inhibition Drug / Drug Interaction Target / Pathway Assays Acute Inflammatory Response Apoptosis Cell Proliferation Cell Viability Glutathione Homeostasis Hepatobiliary Toxicity Kidney Collecting Duct Toxicity Kidney Distal Tubular Toxicity Kidney Proximal Tubule Toxicity Lipidosis Membrane Integrity Metabolism Mitochondrial Function
GENERAL PRINCIPLES OF TOXICOLOGY
GENERAL PRINCIPLES OF TOXICOLOGY Laboratory of toxicology Department of Pharmacology and Toxicology College of Pharmacy, University of Baghdad 2015 TOXICOLOGY - PRACTICAL SYLLABUS 2015 General Principles
More informationBasic toxicology and biomaterials testing
Biomateriaalitiede 2015 Basic toxicology and biomaterials testing Matti Viluksela University of Eastern Finland Department of Environmental Science and National Institute for Health and Welfare Chemicals
More informationBRIDGE THE GAP A Human Pathways Approach to Disease Research
BRIDGE THE GAP A Human Pathways Approach to Disease Research BIOMED 21 Brussels December 8 th, 2015 Brigitte Landesmann Systems Toxicology Unit and EURL ECVAM Institute for Health and Consumer Protection
More informationEnvironmental Risk Assessment Toxicity Assessment
Environmental Risk Assessment Toxicity Assessment UT Evening School Course Spring Semester 2000 Class #07 on February 29, 2000 Environmental Engineering EV595 Martin Clauberg, Ph.D. 1 Outline of discussion
More informationDevelopment of NJ Human Health-based Criteria and Standards
Development of NJ Human Health-based Criteria and Standards Gloria Post NJDEP Office of Science Presented to: Public Health Standing Committee October 18, 2010 Human Health-based Criteria and Standards
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More information5.36 THIOPHANATE-METHYL (077)
391 5.36 THIOPHANATE-METHYL (077) TOXICOLOGY is the International Organization for Standardization (ISO) approved common name for dimethyl 4,4 -(o-phenylene)bis(3-thioallophanate) (International Union
More informationPrinciples of Toxicology: The Study of Poisons
Principles of Toxicology: The Study of Poisons Elizabeth Casarez Department of Pharmacology and Toxicology University it of Arizona The study of the adverse effects of a toxicant on living organisms Adverse
More informationTable of Validated and Accepted Alternative Methods
1 de 8 25/10/2011 13:02 Non-animal Methods for Toxicity Testing Table of Validated and Accepted Alternative Methods Last Updated: September 27, 2011 Validation & Status of Alternative Test Methods & Testing
More information5.17 PENTHIOPYRAD (253)
Penthiopyrad 189 5.17 PENTHIOPYRAD (253) TOXICOLOGY Penthiopyrad is the International Organization for Standardization (ISO) approved name for N-[2- (1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide
More informationConflict of Interest Statement
Specific Aspects and Approaches for Regulatory Evaluation of Pharmaceuticals in Two-Year Rodent Carcinogenicity Studies James A. Popp Stratoxon LLC Morgantown, PA Tel: 610.286.7592 popp@stratoxon.com Conflict
More informationThe liver in poisoning: what can we learn from animal models?
The liver in poisoning: what can we learn from animal models? Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital 4031 Basel/Switzerland Kraehenbuehl@uhbs.ch Outcome and causes of
More informationN-Methylneodecanamide (MNDA)
United States Prevention, Pesticides EPA-730-F-99-008 Environmental Protection And Toxic Substances July 1999 Agency (7505C) New Pesticide Fact Sheet Description of the Chemical N-Methylneodecanamide (MNDA)
More informationFDA Expectations and Evaluation of Inhalation Toxicology Studies
FDA Expectations and Evaluation of Inhalation Toxicology Studies Presented by Timothy McGovern, Ph.D. SciLucent, LLC Herndon, Virginia Development of inhalation products has unique regulatory aspects My
More informationTTI-2341: A Novel Brain-Penetrant, Orally Available, Covalent EGFR Inhibitor for the Treatment of Brain Cancers
TTI-2341: A Novel Brain-Penetrant, Orally Available, Covalent EGFR Inhibitor for the Treatment of Brain Cancers November 2017 2 EGFR is a Drug Target in Brain Cancer Epidermal growth factor receptor (EGFR)
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationIndustrial Toxicology
Industrial Toxicology Learning Objectives Know the assumptions of the doseresponse and time-course curves Be able to define and label key points of a curve Know the difference between potency and efficacy
More informationDistinguishing between Mode and Mechanism of Action
Distinguishing between Mode and Mechanism of Action Michael Dourson Toxicology Excellence for Risk Assessment Center University of Cincinnati College of Medicine Conflict of Interest Statement The research
More informationChapter 5. The Actions of Drugs. Origins of Drugs. Names of Drugs. Most drugs come from plants or are chemically derived from plants
Chapter 5 The Actions of Drugs Origins of Drugs Most drugs come from plants or are chemically derived from plants Names of Drugs Chemical name: Complete chemical description of the molecule Example: N'-[2-[[5-(dimethylaminomethyl)-2-furyl]
More information2. List routes of exposure in the order of most rapid response.
Practice Test questions: 1. What are the two areas of toxicology that a regulatory toxicologist must integrate in order to determine the "safety" of any chemical? 2. List routes of exposure in the order
More informationAssessment and regulation of endocrine disrupters under European chemical legislations Susy Brescia Chemicals Regulation Directorate (CRD) HSE
Health and and Safety Executive Assessment and regulation of endocrine disrupters under European chemical legislations Susy Brescia Chemicals Regulation Directorate (CRD) HSE EDs and the current EU legislative
More informationOverview of US EPA Assessment Activities for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS)
Overview of US EPA Assessment Activities for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) Jennifer Seed, PhD Risk Assessment Division Office of Pollution Prevention and Toxics US
More informationDose-Response Relationship of Essential Metallic Elements. The Application of Categorical Regression Example: Copper
Dose-Response Relationship of Essential Metallic Elements The Application of Categorical Regression Example: Copper Problem: Dose-response relationship for essential trace elements is complex Highly Abnormal
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationA Testing Strategy for the Identification of mammalian Endocrine Disruptors with particular focus on steroids
A Testing Strategy for the Identification of mammalian Endocrine Disruptors with particular focus on steroids Tzutzuy Ramirez, Robert Landsiedel, Susanne Kolle, Hennicke Kamp, Bennard van Ravenzwaay EUSAAT
More informationWhat are the challenges in addressing adjustments for data uncertainty?
What are the challenges in addressing adjustments for data uncertainty? Hildegard Przyrembel, Berlin Federal Institute for Risk Assessment (BfR), Berlin (retired) Scientific Panel for Dietetic Foods, Nutrition
More informationUse of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin
Use of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin WORKSHOP ON MODELLING IN PAEDIATRIC MEDICINES April 2008 Viera Lukacova, Ph.D. Walter Woltosz,
More informationMechanistic Toxicology
SECOND EDITION Mechanistic Toxicology The Molecular Basis of How Chemicals Disrupt Biological Targets URS A. BOELSTERLI CRC Press Tavlor & France Croup CRC Press is an imp^t o* :H Taylor H Francn C'r,,jpi
More informationCHEMICAL IDENTITY. INCI NAME: propylene glycol IUPAC: propane-1,2-diol CAS: EC NUMBER: EMPIRICAL FORMULA: C3H8O2 STRUCTURAL FORMULA:
PROPYLENE GLYCOL CHEMICAL IDENTITY INCI NAME: propylene glycol IUPAC: propane-1,2-diol CAS: 57-55-6 EC NUMBER: 200-338-0 EMPIRICAL FORMULA: C3H8O2 STRUCTURAL FORMULA: PHYSICAL FORM: Colourless Transparent
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationConsiderations in Toxicology Study Design and Interpretation: An Overview Gradient Corporation: Lewis, AS; Beyer, LA; Langlois, CJ; Yu, CJ; Wait, AD
Considerations in Toxicology Study Design and Interpretation: An Overview Gradient Corporation: Lewis, AS; Beyer, LA; Langlois, CJ; Yu, CJ; Wait, AD Introduction The use of animal data to evaluate the
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationDithianon DITHIANON (180)
Dithianon 201 5.11 DITHIANON (180) TOXICOLOGY Dithianon (C 14 H 4 N 2 O 2 S 2 ) is the International Organization for Standardization (ISO) approved name for 5,10-dihydro-5,10-dioxonaphtho[2,3-b]-1,4-dithiine-2,3-dicarbonitrile
More informationRobert G. Sussman, Ph.D., DABT Managing Principal, Eastern Operations. SafeBridge Consultants, Inc. Mountain View, CA New York, NY Liverpool, UK
Robert G. Sussman, Ph.D., DABT Managing Principal, Eastern Operations SafeBridge Consultants, Inc. Mountain View, CA New York, NY Liverpool, UK Paracelsus (1493 1541) All substances are poisons; there
More informationBENZETHONIUM CHLORIDE
OPINION OF THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS CONCERNING BENZETHONIUM CHLORIDE COLIPA n P 70 adopted by the SCCNFP during the 26 th plenary meeting
More informationHOW GOOD ARE VALIDATED METHODS TO PREDICT TOXICITY OF DIFFERENT TYPES OF SUBSTANCES AND PRODUCTS?
HOW GOOD ARE VALIDATED METHODS TO PREDICT TOXICITY OF DIFFERENT TYPES OF SUBSTANCES AND PRODUCTS? VERA ROGIERS Dept. Toxicology Vrije Universiteit Brussel Brussels, Belgium LAYOUT OF THE TALK CURRENT STATUS
More informationPreclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer
Preclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer Scott Laurie MD, FRCPC The Ottawa Hospital Cancer Centre Associate Professor, University of Ottawa Disclosures I have no
More informationBiology 137 Introduction to Toxicology Name Midterm Exam 1 Fall Semester 2001
Biology 137 Introduction to Toxicology Name Midterm Exam 1 Fall Semester 2001 Part I. Multiple choice. Two points each. 1. Toxicology is the study of A. prevalence of disease and death in a population
More informationValproate overdose: what is the role of carnitine?
Valproate overdose: what is the role of carnitine? Ruben Thanacoody National Poisons Information Service (Newcastle) Newcastle upon Tyne Hospitals NHS Trust Medical Toxicology Centre, Newcastle University
More informationHEALTH CONSULTATION. Tom Lea Park EL PASO COUNTY METAL SURVEY EL PASO, EL PASO COUNTY, TEXAS EPA FACILITY ID: TX
HEALTH CONSULTATION Tom Lea Park EL PASO COUNTY METAL SURVEY EL PASO, EL PASO COUNTY, TEXAS EPA FACILITY ID: TX0000605388 September 6, 2002 Prepared by: The Texas Department of Health Under a Cooperative
More informationNew Pesticide Fact Sheet
United States Prevention, Pesticides Environmental Protection And Toxic Substances May 2005 Agency (7505C) New Pesticide Fact Sheet Picaridin Description of the Chemical Use Patterns and Formulations Generic
More informationJustification for the selection of a candidate CoRAP substance
Justification for the selection of a candidate CoRAP substance Substance Name (Public Name): Diethyl phthalate Chemical Group: EC Number: 201-550-6 CAS Number: 84-66-2 Submitted by: Germany/Portugal Published:
More informationPHARMACOLOGY-1 PHL-313. Ali Alhoshani Office: 2B 84
PHARMACOLOGY-1 PHL-313 Ali Alhoshani ahoshani@ksu.edu.sa http://fac.ksu.edu.sa/ahoshani Office: 2B 84 General rules Reference: General rules Email [PHL313-1 st Semester 38-39] Student ID- Question Example
More informationDrugs, Society and Behavior
SOCI 270 Drugs, Society and Behavior Professor Kurt Reymers, Ph.D. Chapter 5 The Actions of Drugs 2011 McGraw-Hill Higher Education. All rights reserved. 1. Drug Facts a. Sources: Most drugs come from
More informationPrinciples of Pharmacology. Pharmacokinetics & Pharmacodynamics. Mr. D.Raju, M.pharm, Lecturer PHL-358-PHARMACOLOGY AND THERAPEUTICS-I
Principles of Pharmacology Pharmacokinetics & Pharmacodynamics PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr. D.Raju, M.pharm, Lecturer Pharmacokinetics Movement of drugs in the body Four Processes Absorption
More informationSerum microrna biomarkers for human DILI
CLEARANCE DRUG bioactivation covalent binding Detoxication GLUCURONIDE SULPHATE DRUG + METABOLITE chemical stress mitochondrial dysfunction apoptosis necrosis hepatocyte hypertrophy hepatocyte hyperplasia
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationSafety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema
Safety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema IRA KALFUS, MD Attune Pharmaceuticals, LLC New York City, NY Andrew McDonald, PhD; Shawn Qian, PhD Attune Pharmaceuticals,
More informationUNIVERSITY OF THE WEST INDIES, ST AUGUSTINE
UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE FACULTY OF MEDICAL SCIENCES SCHOOL OF PHARMACY BACHELOR OF SCIENCE IN PHARMACY DEGREE COURSE SYLLABUS COURSE TITLE: COURSE CODE: BIOPHARMACEUTICS, NEW DRUG DELIVERY
More informationDose response relationships: biological and modeling aspects
Dose response relationships: biological and modeling aspects Jason Aungst, Ph.D. Office of Food Additive Safety Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration The findings
More informationTTC NON-CANCER ORAL DATABASES
TTC NON-CANCER ORAL DATABASES Dr Sue Barlow Consultant in toxicology & risk assessment suebarlow@mistral.co.uk EUROTOX CEC on TTC 13 September 2015 Overview of presentation Rationale for TTC values for
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationInfluence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments
Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments MARIA BIANCA ABRUDAN* 1, DANA MARIA MUNTEAN 1, DANIELA SAVETA POPA 2, LAURIAN VLASE 1, ANA-MARIA
More informationStatus of Activities on BPA
Committed since 2002 to ensuring that Europe s food is safe Status of Activities on BPA at International Level Anna F. Castoldi FIP Unit Meeting with National Experts Parma, 29-30 October 2012 International
More informationClassification of developmentally toxic pesticides, low dose effects, mixtures perspective of the industry
Classification of developmentally toxic pesticides, low dose effects, mixtures perspective of the industry Steffen Schneider 9th Berlin Workshop on Developmental Toxicology Berlin September 13, 2018 What
More informationComments from PlasticsEurope
Polycarbonate/Bisphenol A Group Follow-up Meeting on the Web-Based Public Consulting on Bisphenol A Brussels, April 23 2014 Comments from PlasticsEurope Dieter Beyer Representing the Polycarbonate/Bisphenol
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationThe European Commission non-food Scientific Committees Scientific Committee on consumer safety - SCCS
The European Commission non-food Scientific Committees Scientific Committee on consumer safety - SCCS Health and Consumers Threshold of toxicological concern (TTC) Cosmetics a special case? Thomas Platzek,
More informationOPINION of the French Agency for Environmental and Occupational Health Safety
The Director General Maisons-Alfort, France, 15 June 2009 OPINION of the French Agency for Environmental and Occupational Health Safety Relating to establishing carcinogenic HTVs by inhalation for carbon
More informationDANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR
Research support by Interagency Agreement between NTP/NIEHS and NCTR/FDA The opinions presented are not necessarily those of the U.S. FDA or NTP NCTR/FDA Research on BPA: Integrating pharmacokinetics in
More informationApproaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments
Approaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments Kris Thayer, National Center for Environmental Assessment (NCEA) Integrated Risk Information System (IRIS) Division
More informationRisk Assessment Report on Tris (nonylphenyl)phosphite (TNPP)
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON HEALTH AND ENVIRONMENTAL RISKS SCHER
More informationAN2728 Clinical Data in Atopic Dermatitis
AN2728 Clinical Data in Atopic Dermatitis Karl Beutner, MD, PhD 1 Overview of AN2728 in Atopic Dermatitis Target Product Profile Safe and effective topical therapy for atopic dermatitis Efficacy in the
More informationISRTP Workshop. Cumulative Risk for Endocrine Disrupters: The Case FOR a dose addition approach. Andreas Kortenkamp
ISRTP Workshop Cumulative Risk for Endocrine Disrupters: The Case FOR a dose addition approach Andreas Kortenkamp The School of Pharmacy, University of London 19-20 February 2008 Endocrine disruption:
More informationpresents Introduction to Toxicology and its Role in Green Chemistry
presents Introduction to Toxicology and its Role in Green Chemistry August 6, 2013 12:00 PM 1:00 PM ET Disclaimer: The Michigan Green Chemistry Clearinghouse (MGCC) is committed to providing webinars that
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationFocus Application. Compound-Induced Cytotoxicity
xcelligence System Real-Time Cell Analyzer Focus Application Compound-Induced Cytotoxicity Featured Study: Using the Time Resolving Function of the xcelligence System to Optimize Endpoint Viability and
More informationGeneral Pharmacology MCQs
General Pharmacology MCQs GP01 [Mar96] A drug is given at a dose of 50 mg/kg to a 70 kg man. The plasma concentration after giving it is 10 mg/ml. The elimination half-life is 8 hours. Clearance would
More informationCATEGORY 4 - Rosin adduct esters UVCB CATEGORY JUSTIFICATION DOCUMENT
CATEGORY 4 - Rosin adduct esters UVCB CATEGORY JUSTIFICATION DOCUMENT 1.0 CATEGORY DEFINITION AND ITS MEMBERS This document describes the Rosin adduct esters category and its members as per ECHA guidance
More informationConcepts in Toxicology Food Toxicology Instructor: Gregory Möller, Ph.D. University of Idaho
Concepts in Toxicology Food Toxicology Instructor: Gregory Möller, Ph.D. University of Idaho Learning Objectives Define toxicology and toxicity. Discuss different types of toxic responses. Explain how
More informationThe role of biokinetics in in vitro tests and the interpretation of results. Emanuela Testai
International Symposium on Alternative in vitro methods to characterize the role of EAS in hormone-targeted tissues Rome 17.12.2012 The role of biokinetics in in vitro tests and the interpretation of results
More informationU.S. EPA Endocrine Disruptor Screening Program
U.S. EPA Endocrine Disruptor Screening Program David Dix, Ph.D. Director, Office of Science Coordination and Policy Office of Chemical Safety and Pollution Prevention dix.david@epa.gov April 11 th 2016
More informationThe Importance of ADME/PK to Inform Human Safety Assessments Based on Animal Studies: Example with Furan. Gregory L. Kedderis, PhD Chapel Hill, NC
The Importance of ADME/PK to Inform Human Safety Assessments Based on Animal Studies: Example with Furan Gregory L. Kedderis, PhD Chapel Hill, NC Conflict of Interest None This research was conducted at
More informationZinc: Issues and Update. Craig Boreiko, Ph.D. Ottawa May 2008
Zinc: Issues and Update Craig Boreiko, Ph.D. Ottawa May 2008 Topics Basics of zinc deficiency and essentiality Nutrition vs Toxicology Effects of elevated zinc intake Comparison of risk assessments Concluding
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationData Package of the Peer Consultation Meeting on the Chloroacetanilide Degradates. May 11 th 12 th, Northern Kentucky University, METS Center
Data Package of the Peer Consultation Meeting on the Chloroacetanilide Degradates May 11 th 12 th, 2009 Northern Kentucky University, METS Center 1 (This page intentionally left blank.) 2 Table of Contents
More informationExposure Dose Health Effects
Exposure Dose Health Effects Understanding the links Elaine Symanski, PhD Mary Ann Smith, PhD The starting basis* How are pollutant levels detected and measured in the human body? If there is some level
More informationProactive Integration of Occupational Toxicology Assessments into the Drug Development Process
Proactive Integration of Occupational Toxicology Assessments into the Drug Development Process Greg Erexson, PhD, DABT, ATS 14 July 2015 AbbVie, Inc. North Chicago, IL Disclosure Statement This presentation
More informationThe Comet Assay Tails of the (Un)expected
The Comet Assay Tails of the (Un)expected Use of the in vivo comet assay in pharmaceutical development Bas-jan van der Leede Janssen R&D Johnson & Johnson Pharmaceutical Companies Discovery Sciences Genetic
More informationThreshold Establishment and Rationale. Douglas J Ball, MS, DABT Research Fellow Pfizer Worldwide R&D
Threshold Establishment and Rationale Douglas J Ball, MS, DABT Research Fellow Pfizer Worldwide R&D 1 Objectives Basic Definitions Background on the use of safety thresholds in risk assessment Application
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More informationHealth Effects of Preserved Wood: Relationship Between CCA-Treated Wood and Incidence of Cancer in the United States
Health Effects of Preserved Wood: Relationship Between CCA-Treated Wood and Incidence of Cancer in the United States Daniel C. West, MD Associate Professor of Pediatrics University of California, Davis
More informationHazard Classification: Not classified as hazardous according to OSHA Hazard Communication Standard, 29 CFR
Safety Data Sheet: Stance SnF2 Rinse Concentrate 0.63% SECTION 1: IDENTIFICATION Product Name: Stance - Stannous Fluoride Rinse Concentrate 0.63% Catalog Numbers: Mint & Tropical Fruit - 745246310, 745246313
More informationTopic 3.13 Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances*,
Pure Appl. Chem., Vol. 75, Nos. 11 12, pp. 2151 2158, 2003. 2003 IUPAC Topic 3.13 Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances*, R. Woodrow Setzer,
More informationCumulative Risk: The Argument Against Estrogen Equivalents. Conducting and Assessing the Results of Endocrine Screening
Cumulative Risk: The Argument Against Estrogen Equivalents Conducting and Assessing the Results of Endocrine Screening ISRTP Workshop, Lister Hill Auditorium Bethesda, MD. February 19-20, 2008 Christopher
More informationGeneric Drug Approval Process
1 Generic Drug Approval Process Sharon Ricciardo Katherine P. Weld. M.S., Ph.D. AAVPT Veterinary Drug Regulatory Life Cycle Course March 2, 2011 Overview Background Approval Process Bioequivalence Special
More informationEvaluation of Potential Human Health Effects from Environmental Exposure to Human Pharmaceuticals
Evaluation of Potential Human Health Effects from Environmental Exposure to Human Pharmaceuticals Eileen Hayes, Sc.D. DABT Bristol-Myers Squibb Company for Water Environment Federation Conference - July,
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMethodologies for development of human health criteria and values for the lake Erie drainage basin.
3745-1-42 Methodologies for development of human health criteria and values for the lake Erie drainage basin. [Comment: For dates of non-regulatory government publications, publications of recognized organizations
More informationPerspectives on Evaluating and Managing Cardiovascular Safety Risk for Anticancer Drugs
Perspectives on Evaluating and Managing Cardiovascular Safety Risk for Anticancer Drugs DCTD/DTP/TPB Myrtle Davis, DVM, Ph.D. Chief, Toxicology and Pharmacology Branch Division of Cancer Treatment and
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationChallenges of 21 st Century Toxicology
Challenges of 21 st Century Toxicology Toxicology and Mathematical Modelling 2 nd March 2012 Cameron MacKay Unilever Safety and Environmental Assurance Centre What is Unilever? Consumer goods company Unilever
More informationConcepts in Toxicology
Concepts in Toxicology Instructor: Gregory Möller, Ph.D. University of Idaho Learning Objectives Define toxicology and toxicity. Discuss different types of toxic responses. Explain how toxicants are classified.
More informationPQRI PODP Extractables & Leachables Workshop Leachable Evaluation of a Container Closure System - What to do When Above the Threshold
PQRI PODP Extractables & Leachables Workshop Leachable Evaluation of a Container Closure System - What to do When Above the Threshold William P. Beierschmitt, PhD, DABT, FATS Drug Safety Research and Development
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationTBBPA. 31 August 2014 Green Science Policy Madrid, Spain. National Institutes of Health U.S. Department of Health and Human Services
TBBPA Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. Director, National Institute of Environmental Health Sciences and National Toxicology Program Principle Investigator, National Cancer Institute 31 August
More informationOutline: risk assessment. What kind of environmental risks do we commonly consider? 11/19/2013. Why do we need chemical risk assessment?
Outline: Human health h and ecological l risk assessment Purpose of risk assessment Methodology for quantifying risk Case study: Children s exposure to As from CCA wood staircases Issues practical and
More information